Ruxolitinib is safe and effective for children with AD, according to a study.

Published Date: 04 Nov 2023

Dr. Lawrence Eichenfield stated that there were "no treatment-emergent adverse events suggestive of systemic JAK inhibition" and that there were no noteworthy safety signals in the younger pediatric population.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot